[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 22, 2013

End Points in Trials of Treatments for Skin Infections—Reply

Author Affiliations

Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

Author Affiliations: Trius Therapeutics, San Diego, California (Dr Prokocimer;pprokocimer@triusrx.com); and InClin Inc, San Mateo, California (Dr Das).

JAMA. 2013;309(20):2091-2092. doi:10.1001/jama.2013.4550

In Reply: Dr Spellberg raises the question of whether a cessation of lesion spread in ABSSSIs can be considered a cure of the disease. This issue was discussed by the Foundation for the National Institutes of Health working group on end points in ABSSSIs.1 The group's recommended end point is a 20% or greater decrease in lesion size at the 48- to 72-hour assessment rather than cessation of spread at this time point.